Anju Nohria

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5800011/publications.pdf

Version: 2024-02-01

133 papers	8,353 citations	53751 45 h-index	49868 87 g-index
144 all docs	144 docs citations	144 times ranked	8455 citing authors

#	Article	IF	Citations
1	Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 2018, 71, 1755-1764.	1.2	997
2	Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. Journal of the American College of Cardiology, 2003, 41, 1797-1804.	1.2	571
3	Cardiorenal Interactions. Journal of the American College of Cardiology, 2008, 51, 1268-1274.	1.2	521
4	Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. Journal of Applied Physiology, 2006, 101, 545-548.	1.2	389
5	Medical Management of Advanced Heart Failure. JAMA - Journal of the American Medical Association, 2002, 287, 628.	3.8	386
6	Cancer Therapyâ€"Related Cardiac Dysfunction and Heart Failure. Circulation: Heart Failure, 2016, 9, e002661.	1.6	241
7	Value of Clinician Assessment of Hemodynamics in Advanced Heart Failure. Circulation: Heart Failure, 2008, 1, 170-177.	1.6	225
8	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	1.0	213
9	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. European Heart Journal, 2020, 41, 1733-1743.	1.0	212
10	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. Journal of the American College of Cardiology, 2020, 75, 467-478.	1.2	179
11	Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With LungÂCancer. Journal of the American College of Cardiology, 2019, 73, 2976-2987.	1.2	163
12	Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. European Heart Journal, 2014, 35, 612-623.	1.0	160
13	Rho Kinase Inhibition Improves Endothelial Function in Human Subjects With Coronary Artery Disease. Circulation Research, 2006, 99, 1426-1432.	2.0	155
14	Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. Journal of the American College of Cardiology, 2003, 41, 2029-2035.	1.2	143
15	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitorâ€"Associated Myocarditis. Circulation, 2020, 141, 2031-2034.	1.6	142
16	Ibrutinib-Associated Atrial Fibrillation. JACC: Clinical Electrophysiology, 2018, 4, 1491-1500.	1.3	134
17	The STARBRITE Trial: A Randomized, Pilot Study of B-Type Natriuretic Peptideâ€"Guided Therapy in Patients With Advanced Heart Failure. Journal of Cardiac Failure, 2011, 17, 613-621.	0.7	122
18	Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis, 2009, 205, 517-521.	0.4	119

#	Article	IF	Citations
19	Patient Expectations From Implantable Defibrillators to Prevent Death in Heart Failure. Journal of Cardiac Failure, 2010, 16, 106-113.	0.7	110
20	Cancer Therapyâ€“Related Cardiac Dysfunction and Heart Failure. Circulation: Heart Failure, 2016, 9, e002843.	1.6	109
21	Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2021, 7, 206.	3.4	101
22	Myocardial T1 and T2 Mapping by Magnetic Resonance in PatientsÂWithÂImmune Checkpoint Inhibitorâ€“Associated Myocarditis. Journal of the American College of Cardiology, 2021, 77, 1503-1516.	1.2	97
23	The Novel Coronavirus Disease (COVID-19) Threat for Patients With Cardiovascular Disease and Cancer. JACC: CardioOncology, 2020, 2, 350-355.	1.7	92
24	Evaluation and Monitoring of Patients with Acute Heart Failure Syndromes. American Journal of Cardiology, 2005, 96, 32-40.	0.7	87
25	Cardiotoxicity of Immune Checkpoint Inhibitors. Current Oncology Reports, 2021, 23, 79.	1.8	85
26	Routine Echocardiography Screening for Asymptomatic Left Ventricular Dysfunction in Childhood Cancer Survivors: A Model-Based Estimation of the Clinical and Economic Effects. Annals of Internal Medicine, 2014, 160, 661.	2.0	83
27	The Association Between High-Dose Diuretics and Clinical Stability in Ambulatory Chronic Heart Failure Patients. Journal of Cardiac Failure, 2008, 14, 388-393.	0.7	82
28	Cardiovascular Manifestations From Therapeutic Radiation. JACC: CardioOncology, 2021, 3, 360-380.	1.7	81
29	Abnormal Exercise Response in Long-Term Survivors of HodgkinÂLymphoma Treated With Thoracic Irradiation. Journal of the American College of Cardiology, 2015, 65, 573-583.	1.2	74
30	Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy. JACC: CardioOncology, 2019, 1, 54-65.	1.7	74
31	Mismatch of Right- and Left-Sided Filling Pressures in Chronic Heart Failure. Journal of Cardiac Failure, 2011, 17, 561-568.	0.7	72
32	Chimeric Antigen Receptor T-Cell Therapyâ€“Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma. Circulation, 2020, 142, 1687-1690.	1.6	70
33	GENDER DIFFERENCES IN MORTALITY AFTER MYOCARDIAL INFARCTION. Cardiology Clinics, 1998, 16, 45-57.	0.9	69
34	Comparison of Effects of Rosuvastatin (10 mg) Versus Atorvastatin (40 mg) on Rho Kinase Activity in Caucasian Men With a Previous Atherosclerotic Event. American Journal of Cardiology, 2009, 103, 437-441.	0.7	69
35	Longâ€term cardiovascular mortality after radiotherapy for breast cancer: A systematic review and metaâ€analysis. Clinical Cardiology, 2017, 40, 73-81.	0.7	69
36	Characteristics of Patients Who Die With Heart Failure and a Low Ejection Fraction in the New Millennium. Journal of Cardiac Failure, 2006, 12, 47-53.	0.7	65

#	Article	IF	Citations
37	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
38	Management of Patients With Giant Cell Myocarditis. Journal of the American College of Cardiology, 2021, 77, 1122-1134.	1.2	59
39	Anthracycline Cardiotoxicity. Circulation, 2015, 131, 1946-1949.	1.6	58
40	Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardio-Oncology, 2019, 5, 1.	0.8	54
41	VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. Journal of Heart and Lung Transplantation, 2013, 32, 120-128.	0.3	53
42	Endothelin-1 and Vascular Tone in Subjects With Atherogenic Risk Factors. Hypertension, 2003, 42, 43-48.	1.3	51
43	Testing new targets of therapy in advanced heart failure: The design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain Natriuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. American Heart Journal, 2005, 150, 893-898.	1.2	51
44	Quality of care for patients hospitalized with heart failure at academic medical centers. American Heart Journal, 1999, 137, 1028-1034.	1.2	48
45	Variable Contribution of Heart Failure toÂQuality of Life in Ambulatory HeartÂFailure With Reduced, Better, orÂPreserved Ejection Fraction. JACC: Heart Failure, 2016, 4, 184-193.	1.9	48
46	Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association. Circulation, 2021, 144, e41-e55.	1.6	47
47	Identification and characterization of Î³-giardin and the Î³-giardin gene from Giardia lamblia. Molecular and Biochemical Parasitology, 1992, 56, 27-37.	0.5	45
48	Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic. Trends in Cardiovascular Medicine, 2020, 30, 315-325.	2.3	44
49	Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 315-322.	1.8	43
50	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. JAMA Network Open, 2022, 5, e224304.	2.8	43
51	Immuneâ€related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. European Journal of Heart Failure, 2017, 19, 682-685.	2.9	39
52	Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This?. Current Oncology Reports, 2018, 20, 61.	1.8	39
53	Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitorâ€“Associated Myocarditis. Journal of the American Heart Association, 2020, 9, e018306.	1.6	38
54	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36

#	Article	IF	Citations
55	Prevention of Chemotherapy Induced Cardiomyopathy. Current Heart Failure Reports, 2017, 14, 398-403.	1.3	35
56	The Worst Symptom as Defined By Patients During Heart Failure Hospitalization: Implications for Response to Therapy. Journal of Cardiac Failure, 2012, 18, 524-533.	0.7	34
57	Water and Sodium in Heart Failure: A Spotlight on Congestion. Heart Failure Reviews, 2015, 20, 13-24.	1.7	34
58	Intensity and focus of heart failure disease management after hospital discharge. American Heart Journal, 2005, 149, 715-721.	1.2	33
59	Pacemaker Implantation AfterÂMitral Valve Surgery With AtrialÂFibrillation Ablation. Journal of the American College of Cardiology, 2019, 73, 2427-2435.	1.2	33
60	Pericardial disease in patients treated with immune checkpoint inhibitors. , 2021, 9, e002771.		33
61	Mean Heart Dose Is an Inadequate Surrogate for Left Anterior Descending Coronary Artery Dose and the Risk of Major Adverse Cardiac Events in Lung Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1473-1479.	0.4	33
62	Radiation-Induced Cardiovascular Disease. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 507-517.	0.4	32
63	Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy. Heart, 2019, 105, 34-41.	1.2	32
64	Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines. JACC: Heart Failure, 2022, 10, 559-567.	1.9	32
65	The Effect of Salsalate Therapy on Endothelial Function in a Broad Range of Subjects. Journal of the American Heart Association, 2014, 3, e000609.	1.6	30
66	Cardioâ€oncology care in the era of the coronavirus disease 2019 (COVIDâ€19) pandemic: An International Cardioâ€Oncology Society (ICOS) statement. Ca-A Cancer Journal for Clinicians, 2020, 70, 480-504.	157.7	29
67	Right Ventricular Dysfunction During Intensive Pharmacologic Unloading Persists After Mechanical Unloading. Journal of Cardiac Failure, 2010, 16, 218-224.	0.7	27
68	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell, 2020, 38, 761-766.	7.7	26
69	Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer. Journal of Clinical Oncology, 2020, 38, 3851-3862.	0.8	25
70	Rubbing Salt into Wounds: Hypertonic Saline to Assist with Volume Removal in Heart Failure. Current Heart Failure Reports, 2010, 7, 134-139.	1.3	22
71	Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis. Cancer Causes and Control, 2021, 32, 1395-1405.	0.8	22
72	Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, , 1-10.	2.3	22

#	Article	IF	Citations
73	The risk of reoperative cardiac surgery in radiation-induced valvular disease. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1883-1895.	0.4	21
74	Î²-Adrenergic Blockade for Anthracycline- and Trastuzumab-Induced Cardiotoxicity. Circulation: Heart Failure, 2013, 6, 358-361.	1.6	20
75	Statin Use, Heart Radiation Dose, and Survival in Locally Advanced Lung Cancer. Practical Radiation Oncology, 2021, 11, e459-e467.	1.1	16
76	Transcatheter Compared With Surgical Aortic Valve Replacement in Patients With Previous Chest-Directed RadiationÂTherapy. JACC: CardioOncology, 2021, 3, 397-407.	1.7	15
77	Frequency and impact of delayed decisions regarding heart transplantation on long-term outcomes in patients with advanced heart failure. Journal of the American College of Cardiology, 2004, 43, 794-802.	1.2	14
78	Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer. Lung Cancer, 2016, 96, 41-47.	0.9	14
79	Cardiovascular Complications of Cranial and Neck Radiation. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 45.	0.4	14
80	Incidental Coronary Artery Calcification in Cancer Imaging. JACC: CardioOncology, 2019, 1, 135-137.	1.7	14
81	Reduced Cardiorespiratory Fitness and Increased Cardiovascular Mortality After Prolonged Androgen Deprivation Therapy for Prostate Cancer. JACC: CardioOncology, 2020, 2, 553-563.	1.7	13
82	How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk. JACC: CardioOncology, 2021, 3, 737-741.	1.7	11
83	Short-Term Outcomes of Transcatheter Versus Isolated Surgical Aortic Valve Replacement for Mediastinal Radiation-Associated Severe Aortic Stenosis. Circulation: Cardiovascular Interventions, 2021, 14, e010009.	1.4	10
84	Usefulness of ventilatory inefficiency in predicting prognosis across the heart failure spectrum. ESC Heart Failure, 2022, 9, 293-302.	1.4	10
85	Heart Failure and Diabetes: Collateral Benefit of Chronic Disease Management. Congestive Heart Failure, 2006, 12, 132-136.	2.0	9
86	Should we avoid heart transplantation in cardiomyopathy due to radiotherapy/chemotherapy or amyloidosis? The devil is in the details. Journal of Heart and Lung Transplantation, 2012, 31, 1253-1256.	0.3	9
87	Advanced Heart Failure Due to Cancer Therapy. Current Cardiology Reports, 2015, 17, 16.	1.3	9
88	Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial. Cancer, 2021, 127, 2213-2221.	2.0	9
89	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. JAMA Network Open, 2022, 5, e2142046.	2.8	9
90	Elevated Coronary Artery Calcium Quantified by a Validated Deep Learning Model From Lung Cancer Radiotherapy Planning Scans Predicts Mortality. JCO Clinical Cancer Informatics, 2022, 6, e2100095.	1.0	9

#	Article	IF	Citations
91	Major adverse cardiac event risk prediction model incorporating baseline Cardiac disease, Hypertension, and Logarithmic Left anterior descending coronary artery radiation dose in lung cancer (CHyLL). Radiotherapy and Oncology, 2022, 169, 105-113.	0.3	9
92	Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and CardiogenicÂShock. JACC: CardioOncology, 2019, 1, 141-144.	1.7	8
93	Coronary vasomotor dysfunction portends worse outcomes in patients with breast cancer. Journal of Nuclear Cardiology, 2022, 29, 3072-3081.	1.4	8
94	Observation Is Never Obsolete â^—. JACC: Heart Failure, 2014, 2, 32-34.	1.9	7
95	Coronary vasomotor dysfunction in cancer survivors treated with thoracic irradiation. Journal of Nuclear Cardiology, 2021, 28, 2976-2987.	1.4	7
96	How to Diagnose and Manage Radiation Cardiotoxicity. JACC: CardioOncology, 2020, 2, 655-660.	1.7	6
97	Decoding the link between heart failure and incident cancer. European Heart Journal, 2021, 42, 3060-3062.	1.0	6
98	When Past Is Prologue. New England Journal of Medicine, 2009, 360, 1016-1022.	13.9	5
99	Regional practice norms for the care of childhood cancer survivors at risk for cardiomyopathy: A Delphi study. Pediatric Blood and Cancer, 2019, 66, e27868.	0.8	5
100	Management of acute coronary syndromes in patients with cancer: room for improvement. European Heart Journal, 2019, 40, 1801-1803.	1.0	5
101	Patients report more severe daily limitations than recognized by their physicians. Clinical Cardiology, 2019, 42, 1181-1188.	0.7	4
102	Caseâ€control study of heart rate abnormalities across the breast cancer survivorship continuum. Cancer Medicine, 2019, 8, 447-454.	1.3	4
103	Cancer patients in cardiology: how to communicate with patients with special psychological needs and manage their cardiac problems in daily clinical practice. Journal of Cardiovascular Medicine, 2020, 21, 286-291.	0.6	4
104	Sequential Hypoglycemia, Hyperglycemia, and the Carcinoid Syndrome Arising from A Plurihormonal Neuroendocrine Neoplasm. Endocrine Practice, 2000, 6, 370-374.	1.1	3
105	Therapeutic Adjustments in Stage D Heart Failure: Challenges and Strategies. Current Heart Failure Reports, 2015, 12, 15-23.	1.3	3
106	Dying is not what it used to be! Impact of evolving epidemiology and treatment on mode of death in heart failure. European Journal of Heart Failure, 2019, 21, 1267-1269.	2.9	3
107	The clinical conundrum of managing 5â€fluorouracilâ€“induced vasospasm in colorectal carcinoma. Cancer, 2019, 125, 4346-4349.	2.0	3
108	A Breath-Taking Diagnosis. New England Journal of Medicine, 2019, 380, 81-87.	13.9	3

#	Article	IF	Citations
109	Giant Left Atrium. New England Journal of Medicine, 2008, 358, 2050-2050.	13.9	1
110	Pilot Study of a Hospital-to-Home Program To Reduce Heart Failure Readmissions Led by Heart Failure Nurse Practitioners. Journal of Cardiac Failure, 2011, 17, S100.	0.7	1
111	The Cardiorenal Syndrome: Should Change Make Us Uncomfortable?. Journal of Cardiac Failure, 2011, 17, 1001-1003.	0.7	1
112	Bedside Hemodynamic Profiles in Acute Decompensated Heart Failure: Clinical Uncertainty May Identify Higher Risk. Journal of Cardiac Failure, 2015, 21, S13.	0.7	1
113	Reducing Readmissions With Novel Cardiac Resynchronization Therapy Programming. JACC: Heart Failure, 2015, 3, 573-575.	1.9	1
114	Double Jeopardy: Cancer and Heart Failure. Journal of Cardiac Failure, 2019, 25, 522-523.	0.7	1
115	Temporal Associations and Outcomes of Breast Cancer and HeartÂFailure inÂPostmenopausal Women. JACC: CardioOncology, 2020, 2, 567-577.	1.7	1
116	Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion. Heart Failure Reviews, 2021, 26, 1529-1529.	1.7	1
117	Decision Science Can Inform Clinical Trade-Offs Regarding Cardiotoxic Cancer Treatments. JNCI Cancer Spectrum, 2021, 5, pkab053.	1.4	1
118	Cardiac autonomic dysfunction in breast cancer survivors.. Journal of Clinical Oncology, 2017, 35, 10057-10057.	0.8	1
119	Should Weight Loss Be Targeted During an Acute Heart Failure Admission?. Journal of Cardiac Failure, 2022, 28, 1125-1127.	0.7	1
120	Hemodynamic profiles in heart failure: Reply. Journal of the American College of Cardiology, 2004, 43, 151.	1.2	0
121	What Do Heart Failure Patients Expect from Implantable Defibrillators?. Journal of Cardiac Failure, 2006, 12, S132.	0.7	0
122	Predictive Prognostic Value of Ventilatory Inefficiency across the Spectrum of Heart Failure. Journal of Cardiac Failure, 2019, 25, S31-S32.	0.7	0
123	Anthracycline Cardiotoxicity. JACC: CardioOncology, 2020, 2, 220-222.	1.7	0
124	Association of cancer treatment with excess heart age among young breast cancer survivors.. Journal of Clinical Oncology, 2021, 39, 12081-12081.	0.8	0
125	Medical Management of Hemodynamically Unstable Sinoatrial Node Dysfunction in a Patient With Intracardiac Lymphoma. JACC: CardioOncology, 2021, 3, 326-329.	1.7	0
126	Strategies to balance stroke and bleeding risk in patients with atrial fibrillation and cancer. Heart Rhythm, 2021, 18, 1533-1538.	0.3	0

#	Article	IF	Citations
127	Radiotherapy: Clinical Aspects and Cardiotoxicity. , 2017, , 191-213.		0
128	Evaluation of the Risk of Atrial Fibrillation/Flutter Among Patients Initiating Ibrutinib. Blood, 2018, 132, 4821-4821.	0.6	0
129	Cost-effectiveness of screening guidelines to prevent heart failure in childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).. Journal of Clinical Oncology, 2019, 37, 10052-10052.	0.8	0
130	Cardiorespiratory fitness and cardiovascular mortality after prolonged androgen deprivation therapy for prostate cancer.. Journal of Clinical Oncology, 2019, 37, 11576-11576.	0.8	0
131	Aortic FDG Uptake in Patients WithÂCancer. JACC: CardioOncology, 2020, 2, 771-773.	1.7	0
132	Is worsening renal function relevant without clinical context?. European Journal of Heart Failure, 2022, 24, 375-377.	2.9	0
133	Survival of elderly patients with HER2+/HR- metastatic breast cancer in clinical practice: SEER-Medicare data 2012-2016.. Journal of Clinical Oncology, 2022, 40, 1039-1039.	0.8	0